PMID- 25770728
OWN - NLM
STAT- MEDLINE
DCOM- 20150629
LR  - 20191210
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 85
IP  - 5
DP  - 2015 May
TI  - Solifenacin or mirabegron could improve persistent overactive bladder symptoms 
      after dutasteride treatment in patients with benign prostatic hyperplasia.
PG  - 1151-1155
LID - S0090-4295(15)00107-7 [pii]
LID - 10.1016/j.urology.2015.01.028 [doi]
AB  - OBJECTIVE: To evaluate the clinical response and adverse events (AEs) of 
      solifenacin (SOL) or mirabegron (MIR) in benign prostatic hyperplasia patients 
      with persistent overactive bladder (OAB) symptoms after dutasteride (DUT) 
      treatment. METHODS: Fifty cases with residual OAB symptom score (OABSS) >/= 5 and 
      OABSS Q3 >/= 2 after at least 6 months treatment of DUT were included in this 
      study. Patients were administered 5 mg/d of SOL (N = 25) or 50 mg/d of MIR (N = 
      25), and International Prostate Symptom Score (IPSS) and OABSS were prospectively 
      collected at 4 and 12 weeks. The safety was evaluated by changes in postvoided 
      residual urine volume and the incidence of AEs. RESULTS: After DUT 
      administration, the mean prostate volume, IPSS, and OABSS were 39.0 mL, 17.6, and 
      8.1, respectively. SOL 5 mg significantly reduced the IPSS, OABSS, and OABSS Q3 
      at 4 and at 12 weeks (-3.1, -2.7, -1.3; P <.05); however, 4 patients could not 
      continue the SOL treatment owing to AEs. All patients could continue the 12 weeks 
      of MIR treatment, and MIR 50 mg reduced IPSS and OABSS at 4 weeks and reduced 
      IPSS, OABSS, and the OABSS Q3 (-3.0, -2.5, -0.9; P <.05) at 12 weeks. Postvoided 
      residual urine volume increased by >/= 100 mL after treatment in 2 cases in the SOL 
      group but not in any patient in the MIR group. CONCLUSION: Additional SOL or MIR 
      might result in amelioration of the persistent OAB symptom after DUT treatment in 
      patients with an enlarged prostate.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Maeda, Takahiro
AU  - Maeda T
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan; 
      Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
FAU - Kikuchi, Eiji
AU  - Kikuchi E
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan. 
      Electronic address: eiji-k@kb3.so-net.ne.jp.
FAU - Hasegawa, Masanori
AU  - Hasegawa M
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan.
FAU - Ishioka, Katsura
AU  - Ishioka K
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan.
FAU - Hagiwara, Masayuki
AU  - Hagiwara M
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan.
FAU - Miyazaki, Yasumasa
AU  - Miyazaki Y
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan.
FAU - Shinojima, Toshiaki
AU  - Shinojima T
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan.
FAU - Miyajima, Akira
AU  - Miyajima A
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan.
FAU - Oya, Mototsugu
AU  - Oya M
AD  - Department of Urology, Keio University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20150312
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (5-alpha Reductase Inhibitors)
RN  - 0 (Acetanilides)
RN  - 0 (Adrenergic beta-3 Receptor Agonists)
RN  - 0 (Azasteroids)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Quinuclidines)
RN  - 0 (Tetrahydroisoquinolines)
RN  - 0 (Thiazoles)
RN  - KKA5DLD701 (Solifenacin Succinate)
RN  - MVR3JL3B2V (mirabegron)
RN  - O0J6XJN02I (Dutasteride)
SB  - IM
MH  - 5-alpha Reductase Inhibitors/*therapeutic use
MH  - Acetanilides/*therapeutic use
MH  - Adrenergic beta-3 Receptor Agonists/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Azasteroids/*therapeutic use
MH  - Dutasteride
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscarinic Antagonists/*therapeutic use
MH  - Prospective Studies
MH  - Prostatic Hyperplasia/complications
MH  - Quinuclidines/*therapeutic use
MH  - Solifenacin Succinate
MH  - Tetrahydroisoquinolines/*therapeutic use
MH  - Thiazoles/*therapeutic use
MH  - Urinary Bladder, Overactive/*drug therapy/etiology
EDAT- 2015/03/17 06:00
MHDA- 2015/06/30 06:00
CRDT- 2015/03/16 06:00
PHST- 2014/10/31 00:00 [received]
PHST- 2015/01/13 00:00 [revised]
PHST- 2015/01/23 00:00 [accepted]
PHST- 2015/03/16 06:00 [entrez]
PHST- 2015/03/17 06:00 [pubmed]
PHST- 2015/06/30 06:00 [medline]
AID - S0090-4295(15)00107-7 [pii]
AID - 10.1016/j.urology.2015.01.028 [doi]
PST - ppublish
SO  - Urology. 2015 May;85(5):1151-1155. doi: 10.1016/j.urology.2015.01.028. Epub 2015 
      Mar 12.